Tony Whetton | Director
Stoller Biomarker Discovery Centre

Tony Whetton, Director, Stoller Biomarker Discovery Centre

Anthony Whetton, is Professor of Cancer Cell Biology at University of Manchester and Director of the Stoller Biomarker Discovery Centre and Manchester Precision Medicine Institute. He has published extensively on leukaemia research and stem cell biology. In 1999 he began to develop proteomics for haematology research and this activity has now blossomed into the formation of the £25million Stoller Biomarker Discovery Centre which combines state of the art mass spectrometry, health informatics, immunoassays and molecular pathology to identify biomarkers. The group has, for example, discovered potential curative strategies for Chronic Myeloid Leukaemia and markers of risk for ovarian cancer using proteomics.

Appearances:



Precision 2018 Day 3 @ 09:50

Development of an integrated platform for biomarker and drug target discovery using proteomics

  • The use of innovations in MS-based technologies offers a high capacity throughput proteomic profiling for clinical biochemistry purposes that can be industrialised, as has been achieved at the Stoller Biomarker Discovery Centre
  • Markers of risk in ovarian cancer have been investigated using a SWATH MS approach. We have also identified potential new curative strategies for chronic myeloid leukaemia and polycythaemia vera
  • Combined with validation platforms, this approach offers a quicker route to mechanistic detail/drug targets plus biomarkers for risk and stratification. Linkage of proteomic data to electronic health records through safe haven health informatics allows the integration of complex molecular phenotyping with endotypic data
  • Reduction in time for biomarker development for patient benefit

back to speakers